STEP UP Trial Shows Semaglutide 7.2 mg Achieves Superior Weight Loss vs. 2.4 mg, Placebo, January 17, 2025. https://www.appliedclinicaltrialsonline.com/view/step-up-trial-semaglutide-superior-weight-loss
Moiz, Areesha et al., “Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials”, The American Journal of Cardiology, Volume 222, 2024, 112-130. pubmed.ncbi.nlm.nih.gov/38679221/
“Wegovy: Package Leaflet, Information for the Patient.” Electronic Medicines Compendium. www.medicines.org.uk/emc/files/pil.13800.pdf. Accessed 9 Dec 2024.
Fornes, Abby, et al. “Once-Weekly Semaglutide For Weight Management: A Clinical Review.” Journal of Pharmacy Technology, vol. 38, no. 4, 2022,pp 239-246. https://doi.org/10.1177/87551225221092681.
National Institute for Health and Care Excellence. “Semaglutide For Managing Overweight And Obesity.” Clinical Guidance, NICE (2023). Accessed 4 Dec. 2024. www.nice.org.uk/guidance/ta875/resources/semaglutide-for-managing-overweight-and-obesity-pdf-82613674831813.
Smits, Mark M., and Daniël H. Van Raalte. “Safety of Semaglutide.” Frontiers in Endocrinology, vol. 12, 2021, article 645563. pmc.ncbi.nlm.nih.gov/articles/PMC8294388/.